Skip to main content
padlock icon - secure page this page is secure

Erythropoietin and anemia of cancer

Buy Article:

$59.00 + tax (Refund Policy)

Abstract: Anemia is a common complication of cancer but its causes differ widely. However, a significant number of patients with even early cancer experience a suppression of the action of erythropoietin on the bone marrow, presumably caused by the release of cytokines. The ensuing anemia may be mild and “asymptomatic”. Nevertheless, it drains physical and emotional vigor so necessary in the fight against the underlying disorder. The therapeutic use of recombinant human erythropoietin has been gratifying and in many cases restored to near normal not only the hemoglobin concentration but also the quality of life.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Research Article

Publication date: June 1, 2000

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more